A

Alexion

Global biopharmaceuticals focusing on rare diseases

Global Safety Program Lead - Senior Medical Director

Full-TimeDeadline 12/31/26
$280.9k - $421.3k/yr+ Short-term incentive bonus + Equity-based long-term incentive program
Senior
PhD, MD
Boston, MA, USA
In Person
Biology & Biotech

About the job

Requirements
  • A medical degree or equivalent degree in biomedicine or science.
  • At least 5 years of extensive relevant clinical, safety, and risk management experience in the pharmaceutical, biotechnology, contract research organization, academic, or health authority sectors.
  • A proven track record of successful clinical safety delivery, with demonstrated strategic influence on clinical studies or programs.
  • Ability to collaborate across a matrixed environment and influence cross-functional leaders in clinical development, medical affairs, and regulatory affairs.
  • Thorough knowledge of pharmacovigilance and global safety deliverables, standards, and processes, including pre-launch and post-launch experience.
  • Experience with global regulatory submissions and interactions with major regulatory agencies.
  • Ability to lead, coach, and mentor other safety medical directors and scientists.
  • Availability to travel domestically and internationally.
  • Ability to present complex topics to senior leaders at safety and development governance forums for alignment and endorsement.
Responsibilities
  • Own the safety strategy, delivery, and oversight for assigned assets or indications in partnership with the Global Safety Head.
  • Develop, implement, and apply safety strategy at the asset and study levels.
  • Act as the safety expert accountable for the scientific and clinical safety content of assigned assets or indications.
  • Ensure high-quality delivery of the Safety and Strategy Management Team and Safety Surveillance Team for assigned assets.
  • Set safety team goals aligned with therapeutic-area and product strategy.
  • Own the safety target product profile, safety go/no-go criteria, safety communications and messaging, and toxicity-management guidelines for assigned assets.
  • Represent Global Patient Safety at governance forums, product teams, advisory boards, and other forums where safety is involved.
  • Own the quality of Risk Management Plans, Periodic Safety Reports, compliance, and adherence to pharmacovigilance regulations for assigned assets.
  • Lead responses to complex technical issues involving specific safety aspects of assigned assets.
  • Provide safety input to study designs and study concept delivery within the assigned program.
  • Provide strategic safety knowledge and support to safety medical directors and scientists throughout the clinical programs.
  • Lead safety physicians and scientists in safety strategy, program design, monitoring, data interpretation, communications, post-marketing surveillance, epidemiology, preclinical work, and literature review.
  • Ensure the work of the team complies with Safety, Health and Environment standards and relevant internal and external regulations.
  • Represent the company in regulatory submissions, responses to health authority queries, ethics committees, marketing companies, investigators, and study teams; provide clarifications and resolve safety issues.
  • Support in-licensing opportunities when required.
  • Promote cross-functional, proactive, and solution-oriented team actions and behaviors.
  • Implement new processes, systems, learning, and ways of working.
  • Prioritize risk-mitigation strategies and effective troubleshooting.
  • Line manage a team of safety physicians and scientists.
  • Maintain current knowledge of relevant safety scientific literature and communicate impactful information clearly.
  • Own proper data collection and interpretation to determine risks and inform global market labeling.
  • Deliver balanced and statistically robust analyses of clinical safety data to drive interpretation and develop proposals.
  • Serve as a source of scientific and clinical safety expertise for product teams analyzing and interpreting scientific and clinical safety data.
  • Deputize for the Global Safety Head when required.
Desired Qualifications
  • A PhD or other complementary degree in a scientific discipline.
  • Leading-edge knowledge and expertise supporting excellent independent judgment.
  • Industry conference speaking experience.
  • Clinical safety and research expertise in an appropriate disease area.

About the company

Alexion focuses on discovering, developing, and selling therapies for rare and ultra-rare diseases by targeting the complement system. Its drugs, such as Soliris and Ultomiris, inhibit C5 to block inflammatory cascades, while Strensiq and Kanuma treat metabolic and lysosomal disorders. The company combines in-house R&D with acquisitions to expand its portfolio and leverages AstraZeneca’s global scale to reach patients. Its goal is to improve outcomes for patients with rare diseases and bring these therapies to international markets at premium pricing.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1992

Get referred to Alexion

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AstraZeneca's July 2026 half-year revenue rose 9%, driven partly by Alexion's rare-disease growth.
  • Ultomiris gained FDA Priority Review on June 15, 2026 for IgAN, with Q4 2026 decision.
  • Koselugo's November 2025 adult NF1 approval and ALXN2220 phase 3 expand the pipeline.

What critics are saying

  • EmblemHealth's April 2025 Soliris antitrust suit targets patent settlements and biosimilar delays.
  • Soliris faces biosimilar erosion after March 2025, while Ultomiris still depends on C5-franchise switching.
  • Ultomiris carries meningococcal boxed warnings; a single fatal infection can trigger litigation and prescribing pullback.

What makes Alexion unique

  • Alexion pioneered complement biology, turning C5 inhibition into approved medicines since Soliris, 2007.
  • Ultomiris, Soliris, Strensiq, and Koselugo span hematology, nephrology, endocrinology, and oncology-adjacent rare diseases.
  • AstraZeneca's 2021 acquisition gives Alexion global commercialization scale and deeper trial funding.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Health Savings Account/Flexible Spending Account
  • Unlimited Paid Time Off
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
PR Newswire
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

StartupTicker
Apr 9th, 2024
Clinical Success For Neurimmune

Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases, has, in collaboration with its partner Alexion, advanced its drug candidate ALXN2220 into phase 3. This marks a significant step in the company’s journey to addressing the serious clinical condition ATTR-CM.  Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed, systemic clinical condition that leads to progressive heart failure and high rate of fatality within four years from diagnosis. Despite recent advances in slowing disease progression, there is currently no treatment available to deplete cardiac ATTR amyloid and revert cardiac dysfunction. Schlieren-based startup, Neurimmune, which develops drug candidates for central nervous system (CNS) and related protein aggregation diseases including Alzheimer’s disease, amyotrophic lateral sclerosis, frontotemporal dementia and ATTR cardiomyopathy, is currently testing a drug candidate, ALXN2220 (formerly NI006), a human antibody targeting ATTR Cardiomyopathy. In 2022, Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca’s Rare Disease group, for ALXN2220. Neurimmune is responsible for completion of the phase 1b clinical study on behalf of Alexion, with Alexion incurring certain trial costs. Aside from the phase 1b trial, Alexion is responsible for further clinical development, manufacturing, and commercialization as ALXN2220. The two companies have now initiated the phase 3 of the DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of ATTR-CM

Business Wire
Apr 1st, 2024
Voydeya™ Approved In The Us As Add-On Therapy To Ravulizumab Or Eculizumab For Treatment Of Extravascular Hemolysis In Adults With The Rare Disease Pnh

WILMINGTON, Del.--(BUSINESS WIRE)--VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).1 VOYDEYA is a first-in-class, oral, Factor D inhibitor developed as an add-on to standard-of-care ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) to address the needs of the approximately 10-20% of patients with PNH who experience clinically significant EVH while treated with a C5 inhibitor.2,3. The approval by the US Food and Drug Administration (FDA) was based on positive results from the pivotal ALPHA Phase III trial. Results from the 12-week primary evaluation period of the trial were published in The Lancet Haematology.2. Bart Scott, MD, Professor, Division of Hematology and Oncology at the University of Washington Medical Center, and Professor, Clinical Research Division at Fred Hutchinson Cancer Center, said: “The approval of VOYDEYA offers this small subset of PNH patients an add-on therapy designed to address EVH, while maintaining disease control with ULTOMIRIS or SOLIRIS. Terminal complement inhibition with ULTOMIRIS can address the life-threatening complications of PNH, building on the efficacy and safety of SOLIRIS established over nearly 20 years.”

Business Wire
Mar 25th, 2024
Ultomiris® (Ravulizumab-Cwvz) Approved In The Us For The Treatment Of Adults With Neuromyelitis Optica Spectrum Disorder (Nmosd)

WILMINGTON, Del.--(BUSINESS WIRE)--ULTOMIRIS® (ravulizumab-cwvz) has been approved in the United States (US) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).1. The approval by the US Food and Drug Administration (FDA) was based on positive results from the CHAMPION-NMOSD Phase III trial, which were published in the Annals of Neurology.2 In the trial, ULTOMIRIS was compared to an external placebo arm from the pivotal SOLIRIS® PREVENT clinical trial. ULTOMIRIS met the primary endpoint of time to first on-trial relapse as confirmed by an independent adjudication committee. Zero relapses were observed among ULTOMIRIS patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%, hazard ratio (95% CI): 0.014 (0.000, 0.103), p0.0001).2

PharmiWeb
Nov 28th, 2023
Nice Endorses Only Approved Treatment For Ultra-Rare Wolman Disease For Children Diagnosed Under The Age Of Two: Interview Opportunity

Sebelipase alfa (Kanuma®▼) recommended by NICE as the first treatment for infants with ultra-rare Wolman Disease.  . Kanuma, an enzyme replacement therapy, is the first medicine to be recommended for this life-threatening condition in infants under two years old